ExploreWatchlistsPricing
  1. US-listed companies
  2. Axsome Therapeutics, Inc.
  3. Financials
  4. Research & development

Axsome Therapeutics, Inc. (AXSM)

Market cap
$12.1B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 2025183-2.03%
Dec 31, 2024187+91.00%
Dec 31, 202398+69.02%
Dec 31, 202258-0.20%
Dec 31, 202158-17.34%
Dec 31, 202070+30.94%
Dec 31, 201954+128.33%
Dec 31, 201823+17.72%
Dec 31, 201720-5.86%
Dec 31, 201621

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat